NovaBridge Biosciences
novabridge.comWhat Do They Do?
Develops antibody-based drug candidates for cancer and retinal diseases, including treatments aimed at gastric cancers and wet age-related macular degeneration.
20-F for FY2025, filed Apr 7, 2026Our innovative immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Our core…View ↗
We, through our subsidiary Visara, acquired the rights to VIS-101, a highly differentiated VEGF-A × ANG-2 bispecific biologics in Phase 2…View ↗
Givastomig (also known as “ABL111”, “TJ033721” and “TJCD4B”) is a bispecific antibody targeting Claudin18.2 (“CLDN18.2”), a tumor…View ↗
Who Are Their Customers?
Works with biopharmaceutical partners on developing drug candidates, including shared development of givastomig and partner-led development of ragistomig.
20-F for FY2025, filed Apr 7, 2026
How Are They Changing?
From China operations to a global pipeline
The older report described a portfolio spanning growth hormone, kidney disease, cancer and other drug candidates, alongside a China-focused commercial partnership. The latest report centers on global clinical programs in cancer and retinal disease and describes a platform model using focused subsidiaries and strategic partnerships.
20-F for FY2022, filed May 1, 2023 20-F for FY2025, filed Apr 7, 2026Our innovative immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Our core…View ↗
We, through our subsidiary Visara, acquired the rights to VIS-101, a highly differentiated VEGF-A × ANG-2 bispecific biologics in Phase 2…View ↗
On October 16, 2025, we announced the adoption of a new business model designed to identify and advance high-value therapeutic assets…View ↗
Loading...
